A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.

ABSTRACT: A common theme across multiple successful immunotherapies for cancer is the recognition of tumor-specific mutations (neoantigens) by T cells. The rapid discovery of such antigen responses could lead to improved therapies through the adoptive transfer of T cells engineered to express neoantigen-reactive T cell receptors (TCRs). Here, through CITE-seq (cellular indexing of transcriptomes and epitopes by sequencing) and TCR-seq of non-small cell lung cancer (NSCLC) tumor-infiltrating lymphocytes (TILs), we develop a neoantigen-reactive T cell signature based on clonotype frequency and CD39 protein and CXCL13 mRNA expression. Screening of TCRs selected by the signature allows us to identify neoantigen-reactive TCRs with a success rate of 45% for CD8⁺ and 66% for CD4⁺ T ce

SUBMITTER: Hanada KI 

PROVIDER: S-EPMC9196205 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature